Dimensional Fund Advisors’s Arcutis Biotherapeutics ARQT Stock Holding History

Dimensional Fund Advisors’s Portfolio ARQT Stock Details ARQT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-118,608	Closed	-$383K	–	3392
2023 Q4	$383K	Sell	118,608 -8,669	-7%	-$23.6K	﹤0.01%	3086
2023 Q3	$676K	Sell	127,277 -15,322	-11%	-$130K	﹤0.01%	2998
2023 Q2	$1.36M	Sell	142,599 -295,516	-67%	-$3.28M	﹤0.01%	2872
2023 Q1	$4.82M	Buy	438,115 +67,625	+18%	+$978K	﹤0.01%	2496
2022 Q4	$5.48K	Buy	370,490 +56,547	+18%	+$988K	﹤0.01%	2419
2022 Q3	$6M	Buy	313,943 +1,335	+0.4%	+$30.2K	﹤0.01%	2361
2022 Q2	$6.66M	Buy	312,608 +85,225	+37%	+$1.75M	﹤0.01%	2360
2022 Q1	$4.38M	Buy	227,383 +103,477	+84%	+$1.75M	﹤0.01%	2577
2021 Q4	$2.57M	Buy	123,906 +44,511	+56%	+$886K	﹤0.01%	2787
2021 Q3	$1.89M	Buy	79,395 +32,616	+70%	+$744K	﹤0.01%	2869
2021 Q2	$1.28M	Buy	+46,779	New	+$1.32M	﹤0.01%	2980

Other funds holding ARQT

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Dimensional Fund Advisors's ARQT Position: Q1 2024 in Review

Dimensional Fund Advisors sold out of Arcutis Biotherapeutics (ARQT) in Q1 2024, closing a stake of 118,608 shares — an estimated $383K sold.

Dimensional Fund Advisors first reported a position in ARQT in Q2 2021 and held it in 11 quarters. The position peaked at $6.66M in Q2 2022. 168 funds tracked by Wall St. Rank hold ARQT as of Q1 2024.

Dimensional Fund Advisors reported no remaining Arcutis Biotherapeutics position as of Q1 2024 after selling out during the quarter.
Dimensional Fund Advisors sold 118,608 Arcutis Biotherapeutics shares in Q1 2024, an estimated $383K.
Dimensional Fund Advisors first reported a position in Arcutis Biotherapeutics in Q2 2021 and held it in 11 quarters.
Dimensional Fund Advisors's Arcutis Biotherapeutics position peaked at $6.66M in Q2 2022.
168 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q1 2024.

Based on Dimensional Fund Advisors's 13F filing for Q1 2024, filed 10 May 2024.